Crinetics Pharmaceuticals (CRNX): Assessing Valuation After a 15% Share Price Climb This Month

Crinetics Pharmaceuticals (CRNX) shares have seen a steady climb over the past month, up about 15%, even as the broader trend for the year shows a decline. The company’s healthy revenue growth contrasts with negative earnings, which has sparked some curiosity about its valuation.

See our latest analysis for Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals has regained some momentum following its strong 30-day share price return of nearly 15%. However, the longer-term picture reminds us that biotech stocks can be volatile. Despite negative one-year total shareholder returns, recent gains may reflect shifting investor sentiment toward its growth potential.

If the latest move in Crinetics has you thinking more broadly about opportunity, now is a great time to discover See the full list for free.

With shares jumping but the company still showing negative earnings, the real question is whether Crinetics Pharmaceuticals is currently undervalued or if investors have already factored in all of its expected future growth. Could this be a genuine buying opportunity, or is everything priced in?

Price-to-Book Ratio of 3.3x: Is it justified?

Crinetics Pharmaceuticals is currently priced at a price-to-book (P/B) ratio of 3.3x, which is notably higher than both its industry peers and the broader sector. At a last close price of $40.86, the stock trades at a level that suggests the market expects substantial value creation beyond the company's present book value.

The price-to-book ratio measures how much investors are willing to pay for each dollar of net assets on the balance sheet. For companies like Crinetics, which are still in the growth phase and generating negative earnings, the P/B ratio is often used as a yardstick to judge relative value since traditional profit-based multiples are not meaningful.

Compared to the US Pharmaceuticals industry average P/B of 2.2x and the peer average of 2.6x, Crinetics appears expensive. This signals that investors are assigning a premium in anticipation of future growth. It also means expectations are higher and there is less room for disappointment if progress stalls.

Without a calculated fair ratio to benchmark against, it is unclear whether this premium is warranted or a sign of overheating. See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-Book of 3.3x (OVERVALUED)

However, persistent negative earnings and disappointing year-to-date returns could signal ongoing headwinds. These factors might challenge the optimistic outlook for Crinetics Pharmaceuticals.

Find out about the key risks to this Crinetics Pharmaceuticals narrative.

Another View: Discounted Cash Flow Analysis

While the price-to-book ratio makes Crinetics Pharmaceuticals look overvalued, the SWS DCF model provides a second perspective. According to our DCF estimate, the stock is trading about 7% above its fair value of $38.34 per share, which also signals overvaluation for now. Could different growth or risk assumptions tilt the balance in the future?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Crinetics Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Crinetics Pharmaceuticals Narrative

If you see things differently or would rather investigate the numbers on your own terms, you can create your own analysis in just a few minutes with Do it your way.

A great starting point for your Crinetics Pharmaceuticals research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Unlock the full potential of your portfolio by checking out proven strategies and hidden gems you might be overlooking. The best opportunities often go to those who move first.

• Capitalize on booming digital trends by exploring these 78 cryptocurrency and blockchain stocks as companies reshape the landscape of finance and technology.
• Supercharge your search for consistent income with these 19 dividend stocks with yields > 3%, offering attractive yields above 3%.
• Benefit from cutting-edge breakthroughs in medicine and health by tapping into these 32 healthcare AI stocks, where artificial intelligence is accelerating innovation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com